The HUNT for Heart Failure” Risk Score

Overview

In this population study aim is to evaluate risk factors for heart failure and combine these into a new heart failure risk score. Secondly, the heart failure risk score will be internally and externally validated, and compared with established heart failure risk scores. Additionally, the prevalence of heart failure as well as the distribution of the heart failure risk score in the general population will be evaluated.

Full Title of Study: “Heart Failure Burden and Heart Failure Risk in the General Population in Norway: “The HUNT for Heart Failure” Risk Score”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 30, 2023

Detailed Description

Explore which clinical risk factors or patient characteristics in a general population that are associated with increased risk for heart failure events and combine these into a new population-based heart failure risk score ("The HUNT for heart failure risk score") for predicting heart failure risk Validate the newly developed heart failure risk score internally in the HUNT2 database Compare the predictive ability of the new heart failure risk score with established heart failure risk scores (the ABC Health HF risk score, the Framingham HF risk score) and an established Norwegian cardiovascular risk score (NORRISK 2) Estimate the prevalence of likely ("undiagnosed") heart failure , i.e., patients at high risk of HF, in a general population by using both the established heart failure risk scores and the newly developed heart failure risk score, and compare the heart failure event rate between those at high risk of heart failure and those with established heart failure.

Interventions

  • Other: Heart failure risk estimation
    • Evaluation by heart failure risk score

Arms, Groups and Cohorts

  • Participants in the third wave of the HUNT study
    • General population participating in the third wave of the HUNT study
  • Participants in the second wave of the HUNT study
    • General population participating in the second wave of the HUNT study

Clinical Trial Outcome Measures

Primary Measures

  • Time to incident heart failure event
    • Time Frame: 10 years
    • Time to first heart failure hospitalization or heart failure related visit at the out-patient clinic (events defined according to the ESC 2016 heart failure guidelines)

Secondary Measures

  • Time to death from any cause
    • Time Frame: 10 years
    • Time to death from any cause
  • Time to first heart failure event or death from any cause
    • Time Frame: 10 years
    • Time to first heart failure event (hospitalization or HF related visit at the out-patient clinic) or death from any cause
  • Validity of heart failure risk score
    • Time Frame: 10 years
    • Evaluation of the validity of heart failure risk score

Participating in This Clinical Trial

Inclusion Criteria

  • Participation in the third or second wave of the HUNT study Exclusion Criteria:

  • Not willing to participate – Missing vital data

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 99 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Helse Nord-Trøndelag HF
  • Collaborator
    • Boehringer Ingelheim
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Håvard Dalen, MSc, PhD, Study Chair, Helse Nord-Trøndelag HF

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.